Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EBIT (2019 - 2025)

Historic EBIT for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$126.8 million.

  • Beam Therapeutics' EBIT fell 1906.69% to -$126.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$466.3 million, marking a year-over-year decrease of 15525.67%. This contributed to the annual value of -$415.6 million for FY2024, which is 13546.93% down from last year.
  • Per Beam Therapeutics' latest filing, its EBIT stood at -$126.8 million for Q3 2025, which was down 1906.69% from -$120.2 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' EBIT registered a high of $132.9 million during Q4 2023, and its lowest value of -$200.4 million during Q1 2021.
  • For the 5-year period, Beam Therapeutics' EBIT averaged around -$88.9 million, with its median value being -$100.0 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 60665.84% in 2021, then soared by 24930.38% in 2023.
  • Over the past 5 years, Beam Therapeutics' EBIT (Quarter) stood at -$63.5 million in 2021, then crashed by 40.17% to -$89.0 million in 2022, then surged by 249.3% to $132.9 million in 2023, then tumbled by 175.3% to -$100.0 million in 2024, then fell by 26.76% to -$126.8 million in 2025.
  • Its EBIT was -$126.8 million in Q3 2025, compared to -$120.2 million in Q2 2025 and -$119.3 million in Q1 2025.